Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
作者信息
Epperla Narendranath, Hashmi Hamza, Ahn Kwang W, Allbee-Johnson Mariam, Chen Andy I, Wirk Baldeep, Kanakry Jennifer A, Lekakis Lazaros, Kharfan-Dabaja Mohamed A, Scordo Michael, Riedell Peter A, Jain Tania, Shadman Mazyar, Sauter Craig, Hamadani Mehdi, Herrera Alex F, Ahmed Sairah
机构信息
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
Br J Haematol. 2024 Sep;205(3):1202-1207. doi: 10.1111/bjh.19569. Epub 2024 May 26.
Abstract
摘要
相似文献
1
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.接受嵌合抗原受体T细胞疗法治疗的继发性中枢神经系统淋巴瘤患者的预后：一项国际骨髓移植登记处分析。
Br J Haematol. 2024 Sep;205(3):1202-1207. doi: 10.1111/bjh.19569. Epub 2024 May 26.
2
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.嵌合抗原受体T细胞（CAR-T细胞）疗法治疗原发性和继发性中枢神经系统淋巴瘤：文献系统综述
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):15-21. doi: 10.1016/j.clml.2022.09.008. Epub 2022 Oct 7.
3
Comparison of Survival Outcomes Between Chimeric Antigen Receptor T-Cell Therapy Recipients With and Without Central Nervous System Involvement.接受嵌合抗原受体T细胞疗法的患者中，有中枢神经系统受累与无中枢神经系统受累者生存结果的比较。
Clin Lymphoma Myeloma Leuk. 2025 Aug 7. doi: 10.1016/j.clml.2025.08.001.
4
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.一名接受嵌合抗原受体T细胞疗法治疗的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤患者发生噬血细胞性淋巴组织细胞增生症。
Immunotherapy. 2024;16(18-19):1105-1111. doi: 10.1080/1750743X.2024.2409622. Epub 2024 Oct 17.
5
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
6
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.中枢神经系统淋巴瘤中CD19嵌合抗原受体T细胞（CAR-T）疗法的疗效：多中心经验洞察
Br J Haematol. 2025 Aug;207(2):525-534. doi: 10.1111/bjh.20234. Epub 2025 Jul 1.
7
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry.美国细胞治疗活动的当前趋势与成果，包括国际血液和骨髓移植研究中心登记处对患者前瞻性报告结果的数据收集。
Transplant Cell Ther. 2024 Sep;30(9):917.e1-917.e12. doi: 10.1016/j.jtct.2024.06.021. Epub 2024 Jun 27.
8
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.嵌合抗原受体T细胞疗法治疗中枢神经系统受累的大B细胞淋巴瘤患者：一项系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e142-e151. doi: 10.1016/j.clml.2023.12.012. Epub 2024 Jan 12.
9
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.原发性纵隔大B细胞淋巴瘤的CD19嵌合抗原受体T细胞疗法：CIBMTR分析
Am J Hematol. 2025 Oct;100(10):1792-1802. doi: 10.1002/ajh.70033. Epub 2025 Aug 11.
10
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.SCHOLAR-1 标准对侵袭性 B 细胞淋巴瘤嵌合抗原受体 T 细胞治疗疗效的影响：真实世界的 GELTAMO/GETH 研究。
Transplant Cell Ther. 2023 Dec;29(12):747.e1-747.e10. doi: 10.1016/j.jtct.2023.08.026. Epub 2023 Sep 1.
引用本文的文献
1
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.结外受累对复发或难治性大B细胞淋巴瘤患者CAR T细胞治疗结局的影响——一项多中心队列研究的结果
Blood Cancer J. 2025 Jun 21;15(1):110. doi: 10.1038/s41408-025-01318-5.
2
Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma.全脑放疗联合CART细胞疗法治疗复发/难治性中枢神经系统B细胞淋巴瘤。
Ann Hematol. 2025 Apr;104(4):2495-2505. doi: 10.1007/s00277-025-06378-y. Epub 2025 Apr 25.
3
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.未特指的高级别 B 细胞淋巴瘤：多机构系列中的 CNS 受累和结局。
Blood Adv. 2024 Oct 22;8(20):5355-5364. doi: 10.1182/bloodadvances.2024013791.
本文引用的文献
1
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.CAR T 细胞治疗后继发中枢神经系统淋巴瘤患者的结局：一项多中心队列研究。
J Hematol Oncol. 2023 Nov 9;16(1):111. doi: 10.1186/s13045-023-01508-3.
2
Outpatient CD28-costimulated CAR T-cells for B-cell malignancies with CNS involvement.用于治疗合并中枢神经系统受累的B细胞恶性肿瘤的门诊CD28共刺激嵌合抗原受体T细胞
Am J Hematol. 2023 Nov;98(11):E301-E304. doi: 10.1002/ajh.27051. Epub 2023 Aug 4.
3
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.ASCTCT 弥漫性大 B 细胞淋巴瘤移植和细胞治疗临床实践建议
Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5.
4
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.侵袭性 B-NHL 中所有 CAR-T 患者和 CAR-T 失败后的 CAR-T 围手术期实践模式和生存预测因素。
Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240.
5
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.继发中枢神经系统淋巴瘤患者接受 CD19 导向嵌合抗原受体 T 细胞过继免疫治疗后的毒性反应和应答率。
Neurology. 2022 May 24;98(21):884-889. doi: 10.1212/WNL.0000000000200608. Epub 2022 Mar 29.
6
CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.CD19或CD20嵌合抗原受体T细胞疗法在中枢神经系统淋巴瘤患者中显示出持久的抗肿瘤疗效。
Hum Gene Ther. 2022 Mar;33(5-6):318-329. doi: 10.1089/hum.2021.249.
7
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。
N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.
8
CAR T-cell therapy for secondary CNS DLBCL.嵌合抗原受体 T 细胞疗法治疗继发性中枢神经系统弥漫性大 B 细胞淋巴瘤。
Blood Adv. 2021 Dec 28;5(24):5626-5630. doi: 10.1182/bloodadvances.2021005292.
9
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.自体造血干细胞移植后继以 CD19/22 CAR T 细胞免疫治疗中枢神经系统淋巴瘤。
Blood Cancer J. 2021 Jul 15;11(7):131. doi: 10.1038/s41408-021-00523-2.
10
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?阿基仑赛 CAR T 细胞疗法治疗复发/难治性继发性中枢神经系统非霍奇金淋巴瘤：疗效和毒性相当，但缓解期较短可能需要替代巩固策略？
Bone Marrow Transplant. 2021 Apr;56(4):974-977. doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.
Zotero 插件